LONDON — Regeneron Pharmaceuticals Inc’s COVID-19 antibody cocktail reduces deaths in hospitalized patients who have not mounted their own antibody response, a large British study published on Wednesday found.
The therapy, REGEN-COV, has been granted emergency use authorization for people with mild-to-moderate COVID-19 in the United States, but results from the RECOVERY trial provide the clearest evidence of its effectiveness among hospitalised patients.
It found that the antibody therapy reduced by a fifth the 28-day mortality of people admitted to hospital with COVID-19 whose immune system had not mounted an antibody response, known as…
Keep on reading: Regeneron COVID-19 therapy cuts deaths among hospitalized patients who lack antibodies–study